<DOC>
	<DOCNO>NCT00470379</DOCNO>
	<brief_summary>RATIONALE : Vaccines make peptide may help body build effective immune response kill tumor cell . Giving vaccine therapy together resiquimod may make strong immune response prevent delay recurrence cancer . PURPOSE : This clinical trial study side effect , best dose , best way give vaccine therapy together resiquimod treat patient stage II , stage III , stage IV melanoma completely remove surgery .</brief_summary>
	<brief_title>Vaccine Therapy Resiquimod Treating Patients With Stage II , Stage III , Stage IV Melanoma That Has Been Completely Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety immunization efficacy NY-ESO-1b peptide vaccine resiquimod adjuvant patient completely resect stage II-IV melanoma . - Collect , preliminarily , descriptive data impact regimen time melanoma relapse patient . OUTLINE : This 3-step pilot , dose-escalation study resiquimod . - Step 1 : Patients receive NY-ESO-1b peptide vaccine intradermally topical resiquimod day 1 . A cohort 3-6 patient receive maximal dose resiquimod NY-ESO-1b peptide vaccine . - Step 2 : Patients receive topical NY-ESO-1b peptide vaccine topical resiquimod day 1 . Cohorts 3-6 patient receive escalate dos resiquimod maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity ( DLT ) . - Step 3 : Patients receive topical NY-ESO-1b peptide vaccine topical resiquimod step 2 dose step 2 . Cohorts 3-6 patient receive resiquimod increase amount surface area MTD determine . The MTD define dose precede 2 3 2 6 patient experience DLT . Blood drawn baseline periodically study treatment observation . Samples analyze flow cytometry , monoclonal antibody staining , ELISPOT , ELISA . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 36 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Prior diagnosis melanoma meeting follow criterion : Stage IIIV disease Complete resection disease No current evidence disease HLAA2 positive No known standard therapy disease potentially curative proven capable extend life expectancy exist PATIENT CHARACTERISTICS : ECOG performance status 02 Hemoglobin ≥ 9.0 g/dL Platelet count ≥ 75,000/mm³ AST ≤ 3 time upper limit normal No uncontrolled current infection No known allergy vaccine adjuvant component Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No know immune deficiency PRIOR CONCURRENT THERAPY : See Disease Characteristics More 4 week since prior chemotherapy recover More 4 week since prior biologic therapy No concurrent immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>stage II melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>